Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -66.3%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13M | $25M | $143M | $24M | $9M | $52M | $205M | $157M | $89M | — | — |
| Enterprise Value | $-10642200 | $786994 | $123M | $-6469910 | $-22305935 | $11M | $182M | $127M | $40M | — | — |
| P/E Ratio → | -0.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 27.77 | 43.53 | 284.78 | 56.45 | 18.03 | 56.38 | 9.76 | 355.46 | 8.39 | — | — |
| P/B Ratio | 0.48 | 0.89 | 2.74 | 0.27 | 0.28 | 1.08 | 5.46 | 2.30 | 0.68 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.38 | 245.20 | -15.26 | -46.76 | 11.37 | 8.67 | 287.57 | 3.74 | — | — |
| EV / EBITDA | — | — | — | — | — | — | 0.72 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.0% | 96.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.4% | 21.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -5219.1% | -5219.1% | -8710.0% | -6900.5% | -7189.7% | -4179.5% | 1203.0% | -17210.4% | -512.5% | -645.9% | -2126.4% |
| Net Profit Margin | -4646.1% | -4646.1% | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% | -15906.1% | -483.5% | -634.6% | -2087.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.3% | -66.3% | -56.6% | -47.4% | -58.1% | -170.3% | -482.2% | -70.9% | -140.3% | — | — |
| ROA | -54.6% | -54.6% | -48.4% | -41.1% | -43.1% | -91.2% | -295.6% | -64.3% | -49.8% | -53.4% | -33.5% |
| ROIC | -124.0% | -124.0% | -72.3% | -74.9% | -731.9% | -272.1% | 712.8% | -95.9% | -600.3% | — | — |
| ROCE | -74.5% | -74.5% | -61.4% | -48.1% | -85.7% | -64.5% | 359.5% | -76.7% | -57.6% | -60.9% | -37.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.00 | — | 0.01 | 0.93 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | 0.14 | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.38 | -0.34 | -0.99 | -0.86 | -0.61 | -0.44 | -0.38 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.09 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -6.80 | -57.27 | -102.53 | — | — | — |
Net cash position: cash ($24M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.53 | 12.53 | 4.35 | 12.73 | 4.10 | 3.43 | 4.01 | 7.35 | 14.62 | 8.17 | 8.08 |
| Quick Ratio | 12.53 | 12.53 | 4.35 | 12.73 | 4.10 | 3.04 | 3.67 | 7.35 | 14.62 | 8.55 | 8.08 |
| Cash Ratio | 12.11 | 12.11 | 4.15 | 12.37 | 3.31 | 2.29 | 2.69 | 7.22 | 14.28 | 7.61 | 7.92 |
| Asset Turnover | — | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 | 0.22 | 0.01 | 0.08 | 0.07 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | 0.19 | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 3826.00 | 2972.93 | 275.04 | — | — | 62.61 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $855360 | $851780 | $205460 | $63719 | $57179 | $36019 | $9427 | $6019 | $6382 | $6382 |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying YARW stock.
Yarrow Bioscience Inc's current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
Yarrow Bioscience Inc's return on equity (ROE) is -66.3%. The historical average is -136.5%.
Based on historical data, Yarrow Bioscience Inc is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Yarrow Bioscience Inc has 96.0% gross margin and -5219.1% operating margin.
Key Metrics
Top Statement Risk
Clinical trial funding exhaustion
Metrics are mathematically derived from official filings.
Speculative Valuation Amidst Clinical Uncertainty
As reported in recent financial filings, VYNE trades at a price-to-sales multiple of 49.63, a figure that appears disconnected from fundamental performance and instead reflects market speculation regarding the potential success of the VYN201 program rather than any underlying operational or revenue-generating capacity.
The elevated P/S ratio suggests that investors are pricing the company as a pure-play intellectual property vehicle rather than a commercial entity. This valuation level warrants caution, as it implies significant future success that remains unproven in late-stage clinical trials.
Persistent Erosion of Invested Capital
Based on the provided quarterly data, VYNE's ROIC has remained deeply negative, reaching -152.9% in 2026Q1, which indicates that the company is currently destroying shareholder value as it consumes capital to fund research without generating any offsetting returns on its invested assets.
The consistent decay in ROIC highlights the structural challenge of a pre-revenue biotech model where capital is deployed into high-risk R&D. Investors should monitor whether future clinical milestones can eventually reverse this trend, though current figures suggest a long path to capital efficiency.
Liquidity Buffer Facing Rapid Depletion
According to the latest balance sheet data, VYNE's current ratio has fluctuated significantly, reaching 20.86 in 2026Q1, yet this metric is potentially misleading as it masks the company's reliance on cash reserves to cover ongoing operational burn in the absence of recurring revenue.
While the current ratio appears high, the lack of operational cash flow means that liquidity is strictly finite and dependent on the timing of capital raises. The company's ability to maintain this liquidity position under stress is highly questionable without further dilutive financing.
Misapplication of Traditional Profitability Metrics
As noted in historical financial statements, the use of net margin to evaluate VYNE is fundamentally flawed, as the company's -41.7% net margin in 2026Q1 reflects R&D-driven losses rather than operational inefficiency, obscuring the true value of the underlying BET inhibitor platform.
Analysts should instead focus on the cash runway and clinical milestone progress, as traditional profitability ratios are irrelevant for a firm that has not yet reached commercialization. Relying on net margins in this context may lead to an incorrect assessment of the company's long-term viability.